Intensity Therapeutics Inc. (NASDAQ:INTS) Sees Large Decline in Short Interest

Intensity Therapeutics Inc. (NASDAQ:INTS) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 48,911 shares, a drop of 40.2% from the August 15th total of 81,764 shares. Based on an average trading volume of 45,186 shares, the days-to-cover ratio is presently 1.1 days. Currently, 1.6% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

INTS has been the subject of a number of recent research reports. HC Wainwright boosted their price objective on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Intensity Therapeutics Price Performance

INTS stock traded up $0.01 during mid-day trading on Friday, hitting $3.88. The stock had a trading volume of 14,271 shares, compared to its average volume of 41,296. The firm has a fifty day simple moving average of $4.32 and a 200 day simple moving average of $4.88. The firm has a market capitalization of $12.68 million, a P/E ratio of -1.09 and a beta of 2.76. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a 52 week low of $3.51 and a 52 week high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). As a group, research analysts forecast that Intensity Therapeutics will post -2.64 EPS for the current year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.